Storm Therapeutics (formerly Iceni Therapeutics) is a drug discovery and development company focused on the identification and development of small molecules that target RNA-modifying enzymes.
The company is a spin-out from the University of Cambridge’s Gurdon Institute and was created to commercialise the ground-breaking work of its founders, Professor Tony Kouzarides and Professor Eric Miska, in the field of RNA epigenetics.
RNA (ribonucleic acid) is the template of all protein synthesis and has key regulatory functions in cells. There is growing understanding of the importance of RNA modification in the development of cancer, opening up novel therapeutic targets in cancer treatment.
Storm Therapeutics intends to develop therapeutics, using IP licensed from Cambridge Enterprise (the commercialisation arm of the University of Cambridge). The proceeds of the funding will be used to identify small molecule modulators of these novel targets in RNA modification pathways and develop them into new classes of anti-cancer treatments.